
Opinion|Videos|December 5, 2025
Introductions
Panelists introduce key CDK4/6 inhibitor data from ESMO 2025, setting the stage for insightful discussions on pivotal clinical trials and questions.
Advertisement
Episodes in this series
In this opening segment, the panelists introduce themselves and set the stage for the series, outlining the purpose of the discussion and the key CDK4/6 inhibitor data featured at ESMO 2025. Viewers are oriented to the trials that will anchor the conversation and the clinical questions the experts aim to explore throughout the program.
Newsletter
Stay informed on drug updates, treatment guidelines, and pharmacy practice trends—subscribe to Pharmacy Times for weekly clinical insights.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Pharmacy Times
1
What Pharmacists Should Know About Long COVID and Brain Health
2
Expert: Why Cutting Alcohol May Enhance GLP-1 Outcomes in Patients With Obesity and Diabetes Risk
3
Depression May Be an Early Manifestation of Neurodegenerative Changes Leading to Movement Disorders
4
Pharmacist Strategies for Navigating Supplement Use in Patients on TNF Inhibitors
5















